Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota.
Division of Gastroenterology/Hepatology, Department of Internal Medicine, Medical College of Georgia, Augusta University, Augusta, Georgia.
Clin Gastroenterol Hepatol. 2017 Dec;15(12):1844-1854. doi: 10.1016/j.cgh.2017.08.023. Epub 2017 Aug 22.
The purpose of this clinical practice update expert review is to describe the key principles in the use of surgical interventions and device-aided therapy for managing fecal incontinence (FI) and defecatory disorders. The best practices outlined in this review are based on relevant publications, including systematic reviews and expert opinion (when applicable). Best Practice Advice 1: A stepwise approach should be followed for management of FI. Conservative therapies (diet, fluids, techniques to improve evacuation, a bowel training program, management of diarrhea and constipation with diet and medications if necessary) will benefit approximately 25% of patients and should be tried first. Best Practice Advice 2: Pelvic floor retraining with biofeedback therapy is recommended for patients with FI who do not respond to the conservative measures indicated above. Best Practice Advice 3: Perianal bulking agents such as intra-anal injection of dextranomer may be considered when conservative measures and biofeedback therapy fail. Best Practice Advice 4: Sacral nerve stimulation should be considered for patients with moderate or severe FI in whom symptoms have not responded after a 3-month or longer trial of conservative measures and biofeedback therapy and who do not have contraindications to these procedures. Best Practice Advice 5: Until further evidence is available, percutaneous tibial nerve stimulation should not be used for managing FI in clinical practice. Best Practice Advice 6: Barrier devices should be offered to patients who have failed conservative or surgical therapy, or in those who have failed conservative therapy who do not want or are not eligible for more invasive interventions. Best Practice Advice 7: Anal sphincter repair (sphincteroplasty) should be considered in postpartum women with FI and in patients with recent sphincter injuries. In patients who present later with symptoms of FI unresponsive to conservative and biofeedback therapy and evidence of sphincter damage, sphincteroplasty may be considered when perianal bulking injection and sacral nerve stimulation are not available or have proven unsuccessful. Best Practice Advice 8: The artificial anal sphincter, dynamic graciloplasty, may be considered for patients with medically refractory severe FI who have failed treatment or are not candidates for barrier devices, sacral nerve stimulation, perianal bulking injection, sphincteroplasty and a colostomy. Best Practice Advice 9: Major anatomic defects (eg, rectovaginal fistula, full-thickness rectal prolapse, fistula in ano, or cloaca-like deformity) should be rectified with surgery. Best Practice Advice 10: A colostomy should be considered in patients with severe FI who have failed conservative treatment and have failed or are not candidates for barrier devices, minimally invasive surgical interventions, and sphincteroplasty. Best Practice Advice 11: A magnetic anal sphincter device may be considered for patients with medically refractory severe FI who have failed or are not candidates for barrier devices, perianal bulking injection, sacral nerve stimulation, sphincteroplasty, or a colostomy. Data regarding efficacy are limited and 40% of patients had moderate or severe complications. Best Practice Advice 12: For defecatory disorders, biofeedback therapy is the treatment of choice. Best Practice Advice 13: Based on limited evidence, sacral nerve stimulation should not be used for managing defecatory disorders in clinical practice. Best Practice Advice 14: Anterograde colonic enemas are not effective in the long term for management of defecatory disorders. Best Practice Advice 15: The stapled transanal rectal resection and related procedures should not be routinely performed for correction of structural abnormalities in patients with defecatory disorders.
本临床实践更新专家评论的目的是描述用于管理粪便失禁 (FI) 和排便障碍的手术干预和器械辅助治疗的关键原则。本综述中概述的最佳实践基于相关出版物,包括系统评价和专家意见(适用时)。
最佳实践建议 1:应遵循逐步的方法来管理 FI。保守治疗(饮食、液体、改善排空的技术、排便训练计划、通过饮食和药物管理腹泻和便秘,如果必要的话)将使大约 25%的患者受益,应首先尝试。
最佳实践建议 2:对于对上述保守措施无反应的 FI 患者,建议进行盆底肌肉再训练和生物反馈治疗。
最佳实践建议 3:当保守措施和生物反馈治疗失败时,可以考虑经肛门注射葡聚糖胶等肛门周围填充剂。
最佳实践建议 4:对于在保守措施和生物反馈治疗 3 个月或更长时间后症状仍未缓解且这些治疗无禁忌症的中重度 FI 患者,应考虑骶神经刺激。
最佳实践建议 5:在有更多证据之前,不建议在临床实践中使用经皮胫神经刺激来管理 FI。
最佳实践建议 6:对于保守或手术治疗失败的患者,或对于保守治疗失败且不希望或不符合更具侵入性干预条件的患者,应提供屏障装置。
最佳实践建议 7:对于产后 FI 患者和近期括约肌损伤的患者,应考虑行肛门括约肌修复术(括约肌成形术)。对于后来出现 FI 症状且对保守和生物反馈治疗无反应且有括约肌损伤证据的患者,如果不能进行经皮胫神经刺激或经肛周围填充注射和骶神经刺激治疗,或这些治疗无效,则可考虑行括约肌成形术。
最佳实践建议 8:对于患有药物难治性严重 FI 的患者,人工肛门括约肌、动力性臀肌成形术可作为治疗选择,这些患者已经接受过治疗或不适合使用屏障装置、骶神经刺激、肛门周围填充注射、括约肌成形术和结肠造口术。
最佳实践建议 9:对于存在重大解剖缺陷(例如直肠阴道瘘、全层直肠脱垂、肛门瘘或类似肛门闭锁的畸形)的患者,应通过手术纠正。
最佳实践建议 10:对于保守治疗失败且不适合或不能使用屏障装置、微创外科干预和括约肌成形术的严重 FI 患者,应考虑结肠造口术。
最佳实践建议 11:对于药物难治性严重 FI 患者,对于不能使用或不适合使用屏障装置、经肛周围填充注射、骶神经刺激、括约肌成形术或结肠造口术的患者,可考虑使用磁控肛门括约肌装置。关于疗效的数据有限,40%的患者有中度或重度并发症。
最佳实践建议 12:对于排便障碍,生物反馈治疗是首选治疗方法。
最佳实践建议 13:基于有限的证据,骶神经刺激不应在临床实践中用于治疗排便障碍。
最佳实践建议 14:逆行性结肠灌肠术长期治疗排便障碍无效。
最佳实践建议 15:吻合器经肛直肠切除术和相关手术不应常规用于纠正排便障碍患者的结构性异常。